A Systematic Review of Efficacy and Safety of Difelikefalin in Treating Pruritus in Hemodialysis Patients with Chronic Kidney Disease

Authors

  • Muljani Enggalhardjo Department of Dermato-Venereology, Faculty of Medicine, Pelita Harapan University, Karawaci, Tangerang, Banten, Indonesia
  • Gabriella Hilary Tumiwa Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia
  • Yeshiza Khosasih Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia

DOI:

https://doi.org/10.19166/med.v13i2.8109

Keywords:

Pruritus, Hemodialysis, Chronic Kidney Disease, Difelikefalin

Abstract

Background: Chronic Kidney Disease (CKD) is a type of kidney disease that gradual loss of kidney function over a period of months or years, usually more than 3 months. Uremic pruritus or chronic kidney disease-associated with CKD (CKD-aP) is a common complication that experienced by CKD patients especially for patients undergoing haemodialysis and it will negatively impact quality of life, for example depression, poor sleep quality, and miss dialysis sessions.

Methods: Three online databases were used for the literature search: Science Direct, Embase, and PubMed. obtaining the information in January 2024. Using specific keywords, a comprehensive analysis of research articles was carried out. We examined the safety and effectiveness of difelikefalin in the management of pruritus in patients receiving hemodialysis who have chronic kidney disease.

Result: Six studies were evaluated that met the criteria for inclusion. The efficacy of difelikefalin in all studies was examined by using WI-NRS as assessment tools for the primary outcome, and for the secondary outcome, skindex-10 or skindex-16 scoring, the 5-D itch scale, and the itch MOS (Medical Outcome Study) sleep disturbance scale were used. From all studies, difelikefalin in various dosages and routes (oral and intravenous) improved pruritus reduction in hemodialysis patients with CKD over placebo. However, in the majority of cases, difelikefalin caused a higher chance of experiencing adverse events than in the placebo group.

Conclusions: All studies show a greater pruritus reduction in hemodialysis patients receiving therapy over placebo, with the optimal benefit-risk at 0.5 μg/kg of difelikefalin, despite unclear efficacy-dosage connections.

References

1. Shirazian S, Aina O, Park Y, Chowdhury N, Leger K, Hou L, et al. Chronic kidney disease-associated pruritus: Impact on quality of life and current management challenges. International Journal of Nephrology and Renovascular Disease. 2017;10:11-26. https://doi.org/10.2147/ijnrd.s108045

2. Sukul N, Karaboyas A, Csomor PA, Schaufler T, Wen W, Menzaghi F, et al. Self-reported pruritus and clinical, dialysis-related, and patient-reported outcomes in hemodialysis patients. Kidney Medicine. 2021;3(1). https://doi.org/10.1016/j.xkme.2020.08.011

3. Plewig N, Ofenloch R, Mettang T, Weisshaar E. The course of chronic itch in hemodialysis patients: Results of a 4”year follow”up study of GEHIS (German epidemiological hemodialysis itch study). Journal of the European Academy of Dermatology and Venereology. 2019;33(7):1429-35. https://doi.org/10.1111/jdv.15483

4. Fishbane S, Jamal A, Munera C, Wen W, Menzaghi F. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. New England Journal of Medicine. 2020;382(3):222-32. https://doi.org/10.1056/nejmoa1912770

5. Yosipovitch G, Awad A, Spencer RH, Munera C, Menzaghi F. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus. Journal of the American Academy of Dermatology. 2023;89(2):261-8. https://doi.org/10.1016/j.jaad.2023.03.051

6. Narita I, Tsubakihara Y, Uchiyama T, Okamura S, Oya N, Takahashi N, et al. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis. JAMA Network Open. 2022;5(5). https://doi.org/10.1001/jamanetworkopen.2022.10339

7. Fishbane S, Mathur V, Germain MJ, Shirazian S, Bhaduri S, Munera C, et al. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients. Kidney International Reports. 2020;5(5):600-10. https://doi.org/10.1016/j.ekir.2020.01.006

8. Topf J, Wooldridge T, McCafferty K, Schömig M, Csiky B, Zwiech R, et al. Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies. Kidney Medicine. 2022;4(8):100512. https://doi.org/10.1016%2Fj.xkme.2022.100512

9. Fishbane S, Wen W, Munera C, Lin R, Bagal S, McCafferty K, et al. Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program. Kidney Medicine. 2022;4(8):100513. https://doi.org/10.1016%2Fj.xkme.2022.100513

Downloads

Published

2024-03-13

Issue

Vol. 13 No. 2 (2024): February

Section

Review Article

License

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.